12.30

0.24% -0.03

Avid Bioservices Inc (CDMO)

Overview News Price History Option Chain Financials Why CDMO Down? Discussions Forecast Stock Split

Avid Bioservices Inc stock is traded at $12.30, with a volume of 1.02M. It is down -0.24% in the last 24 hours and up +0.65% over the past month. Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Previous Close:

$12.33

Open:

$12.31

24h Volume:

1.02M

Relative Volume:

0.55

Market Cap:

$786.75M

Revenue:

$139.91M

Net Income/Loss:

$-140.75M

P/E Ratio:

-273.94

EPS:

-0.0449

Net Cash Flow:

$-20.85M

1W Performance:

-0.32%

1M Performance:

+0.65%

6M Performance:

+80.62%

1Y Performance:

+98.39%

1-Day Range:

$12.29

$12.34

1-Week Range:

$12.28

$12.38

52-Week Range:

$5.65

$12.48

Avid Bioservices Inc Stock (CDMO) Company Profile

Name

Avid Bioservices Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

714.508.6100

Address

14191 MYFORD ROAD, TUSTIN, CA

Employee

371

Twitter

Next Earnings Date

2024-09-09

Latest SEC Filings

CDMO's Discussions on Twitter

Compare CDMO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CDMO Avid Bioservices Inc	12.30	786.75M	139.91M	-140.75M	-20.85M	-2.21
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Avid Bioservices Inc Stock (CDMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-23	Initiated	William Blair	Mkt Perform
Mar-14-23	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Dec-08-21	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-17-21	Initiated	RBC Capital Mkts	Outperform
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-10-19	Upgrade	First Analysis Sec	Outperform → Strong Buy
Oct-17-19	Initiated	Stephens	Overweight
Oct-16-19	Initiated	Craig Hallum	Buy
Jun-28-19	Upgrade	Janney	Neutral → Buy
May-09-19	Downgrade	Janney	Buy → Neutral

View All

Avid Bioservices Inc Stock (CDMO) Latest News

Dec 19, 2024

Avid Bioservices Files Definitive Proxy Statement and Mails Letter to Stockholders - Marketscreener.com

Dec 19, 2024

Dec 18, 2024

Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction - GlobeNewswire

Dec 18, 2024

Avid Bioservices Shareholders to Vote on $1.1B Buyout Deal at $12.50/Share Premium - StockTitan

Dec 18, 2024

Fmr LLC Increases Stake in Avid Bioservices, Inc. (NASDAQ:CDMO) - MarketBeat

Dec 18, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avid Bioservices, Inc. (CDMO) and Encourages Stockholders to Learn More About the Investigation - AccessWire

Dec 18, 2024

Dec 17, 2024

Lord Abbett & CO. LLC Takes $6.19 Million Position in Avid Bioservices, Inc. (NASDAQ:CDMO) - MarketBeat

Dec 17, 2024

Dec 15, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Avid Bioservices, Inc. (CDMO) Investors to Inquire about Securities Investigation - AccessWire

Dec 15, 2024

Dec 13, 2024

Avid Bioservices (CDMO) Can Exploit Potential U.S. BIOSECURE Act - MSN

Dec 13, 2024

Avid Bioservices' SWOT analysis: stock poised for private equity takeover By Investing.com - Investing.com Australia

Dec 13, 2024

GLAZER CAPITAL, LLC Acquires Significant Stake in Avid Bioservic - GuruFocus.com

Dec 13, 2024

Avid Bioservices' SWOT analysis: stock poised for private equity takeover - Investing.com India

Dec 13, 2024

Dec 12, 2024

Avid Bioservices: Fiscal Q2 Earnings Snapshot - CT Insider

Dec 12, 2024

Dec 11, 2024

Stephens keeps Avid Bioservices shares at Equal Weight on developments By Investing.com - Investing.com Canada

Dec 11, 2024

Avid Bioservices Reports Revenue Growth Amid Acquisition Plans - TipRanks

Dec 11, 2024

Vascular Disrupting Agents Market Top Companies StudyAGC - openPR

Dec 11, 2024

Dec 10, 2024

Avid Bioservices Reports Q2 Revenue of $33.5M, Misses Estimate; EPS at -$0.27, Wider Than Expected - GuruFocus.com

Dec 10, 2024